Empliciti is indicated in combination with lenalidomide and dexamethasone to treat multiple myeloma in patients who have received at least one prior therapy.
In a randomised open-label phase III trial in 646 patients with relapsed or refractory multiple myeloma, addition of elotuzumab to lenalidomide and dexamethasone treatment produced a significant relative reduction of 30% in the risk of disease progression or death. Median progression-free survival in the elotuzumab group was 19.4 months, compared with 14.9 months in the control group (p<0.001).
The overall response rate in the elotuzumab group was 79%, versus 66% in the control group (p<0.001).
Before being treated with elotuzumab, patients must receive premedication with dexamethasone, an H1 blocker, an H2 blocker and paracetamol to reduce the risk of infusion reactions. Other very common adverse events seen with the antibody in clinical trials were diarrhoea, herpes zoster, nasopharyngitis, cough, pneumonia, upper respiratory tract infection, lymphopenia and weight loss. The most serious adverse reaction that can occur during treatment is pneumonia.